Imuran (Azathioprine)

Azathioprine is a prodrug that is converted inside cells to 6‑mercaptopurine, a purine analog. This metabolite interferes with DNA and RNA synthesis, which limits the proliferation of T and B lymphocytes. By reducing the number of active immune cells, azathioprine dampens the immune response that drives transplant rejection and autoimmune inflammation.

The dose of Imuran is individualized by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and response to therapy. Dosage adjustments are made during treatment to balance efficacy with safety, and patients should follow the prescriber’s instructions without self‑adjusting the amount.

The safety of azathioprine in pregnancy and lactation is not fully established. Clinicians weigh potential benefits against possible risks to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss their situation with a healthcare professional before starting or continuing treatment with Imuran.

To request Imuran, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Azathioprine belongs to the thiopurine class, which differs from calcineurin inhibitors (such as cyclosporine) and mTOR inhibitors (such as sirolimus). Compared with those agents, azathioprine generally has a slower onset of action but is often used for long‑term maintenance because of its oral formulation and cost‑effectiveness. The choice of therapy depends on the clinical scenario and physician judgment.

Imuran tablets should be stored at room temperature, below 25 °C. Keep them in the original container, protect from moisture and direct sunlight, and ensure the packaging is tightly closed to maintain stability throughout the shelf life.

Imuran is taken orally as a tablet, usually with food or a glass of water to reduce gastrointestinal irritation. The exact timing and frequency are determined by the prescribing clinician, who may adjust the schedule based on therapeutic response and laboratory monitoring.

The most serious risks include severe bone‑marrow suppression leading to infections, hepatotoxicity with possible liver failure, pancreatitis, and an increased long‑term risk of certain cancers such as lymphoma. Patients should undergo regular blood and liver function tests to detect these complications early.

Imuran is contraindicated in patients with known hypersensitivity to azathioprine or any of its components, those with severe bone‑marrow failure, active infections, or uncontrolled liver disease. It should also be used with caution in individuals with renal impairment, pregnant or nursing women, and patients receiving live vaccines.